Veritas Genetics reaches an agreement with Apposite Capital and other shareholders, for the full acquisition of NIMGenetics, leading the future of medical genetics January 16, 2025
Veritas Genetics participates in a groundbreaking study highlighting the importance of polygenic risk scores in the clinical management of breast cancer patients October 4, 2024
Veritas Genetics at the forefront of genomic screening with new studies presented at the European Society of Human Genetics Conference – ESHG 2024 May 30, 2024
Veritas participated at HUGO 2024 with a presentation on Elective Genome Screening and a groundbreaking abstract demonstrating the effective utilization of Polygenic Risk Scores April 12, 2024
Veritas Genetics will host a corporate satellite at ESHG 2023 titled “Elective genomic screening: Its role in clinical practice and general health checks” June 6, 2023
